A new depression treatment developed by startup Neumora Therapeutics failed in a Phase 3 clinical trial — the company’s first late-stage readout.
The drug, navacaprant, failed to show a meaningful improvement in depression scores compared to placebo, the company reported Thursday. Both the treatment group and the placebo group reported a 12.5-point reduction in their scores. The drug also failed to show a statistically significant improvement on a scoring system measuring participants’ ability to experience pleasure, when compared to placebo.
This is the first of three Phase 3 studies that Neumora has planned for navacaprant.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in